Piper Sandler initiated coverage of BioAge Labs (BIOA) with an Overweight rating and $73 price target The company’s BGE-102 is an oral QD CNS-penetrant NLRP3 inhibitor small-molecule with “strong” Phase 1 data in obese patients, the analyst tells investors in a research note. Piper views BioAge as a “key name to own.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
- BioAge Labs Announces Upsized Public Equity Offering
- Closing Bell Movers: Netflix down 5% after soft guidance
- BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating
- BioAge Labs announces $75M common stock offering